ReviewAnnual review of pharmacology and toxicology2019
Modulating NRF2 in Disease: Timing Is Everything.
Review in Annual review of pharmacology and toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 301 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
301 citing papers in PubMed, 1 synthesis or guideline pooled it, 480 citations in OpenAlex.
- Insight into Nrf2: a bibliometric and visual analysis from 2000 to 2022.Frontiers in genetics · 2023Pooled it
- The role of iron in normal and impaired testicular function.Andrology · 2026Review
- Review
- A novel Keap1-Nrf2 inhibitor 6K delays the progression of AKI-to-CKD by mitigating maladaptive repair.Redox biology · 2026Article
- NRF2-mediated immune evasion and ferroptosis resistance in hepatocellular carcinoma: implications for immune checkpoint inhibitor response.Journal of liver cancer · 2026Article
- Nrf2 as a therapeutic target of ginseng: A comprehensive review from preclinical evidence to clinical applications.Journal of ginseng research · 2026Review
- The Effect of Curcumin and its Analogs C66 and B2BrBC on Key Biomarkers of Oxidative Stress in Breast Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Calycosin protects against post-myocardial infarction heart failure by activating the NRF2/HO-1 signaling pathway.Journal of thoracic disease · 2026Article
- Ginsenoside Rg1 Alleviates Lead-Induced Neurotoxicity Through Nrf2-Associated Modulation of Oxidative Stress and Ferroptosis.Molecules (Basel, Switzerland) · 2026Article
- Ferroptosis Resistance: Redundant Antioxidant Networks Are a Barrier to Cancer Therapy.Antioxidants (Basel, Switzerland) · 2026Review
- Organic Germanium (Ge-132) Reduces Glycative Damage While Maintaining Cellular Stress Signaling, Revealing Limited Coordination Between Biochemical and Cellular Responses.Molecules (Basel, Switzerland) · 2026Article
- Pharmacological Activation of NRF2 by Omaveloxolone Upregulates NRF2-Target Proteins in SMA Type I Human Fibroblasts.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Toll-like receptor 9 arginine methylation promotes ferroptosis in prostate cancer through the NRF2/GPX4 signaling pathway.Translational andrology and urology · 2026Article
- The Biological Basis, Mechanisms of Action, and Optimization Strategies of Exosomes Derived from Mesenchymal Stem Cells for the Treatment of Alzheimer's Disease.Molecular neurobiology · 2026Review
- Astrocytic Redox Homeostasis as a Metabolic Modulator of DNA Damage and Repair in the Ischemic Penumbra.Cells · 2026Review
- Keap1-Inhibitory Peptides fromMolecules (Basel, Switzerland) · 2026Article
- Grape Seed Proanthocyanidins Enhance Time-Dependent HO-1 Activation and Improve Redox Homeostasis in Obesity-Induced Hepatic Dysfunction.Antioxidants (Basel, Switzerland) · 2026Article
- Effects and Mechanisms of Stevioside on Metabolic Dysfunction-Associated Steatotic Liver Disease.Food science & nutrition · 2026Review
- Western diet induces iron-dependent enteric neurodegeneration via ferroptosis.The Journal of clinical investigation · 2026Article
- Tipping the balance: NRF2's dual role in ferroptotic fate.Oncogenesis · 2026Review
241 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The transcription factor nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) is a central regulator of redox, metabolic, and protein homeostasis that intersects with many other signaling cascades. Although the understanding of the complex nature of NRF2 signaling continues to grow, there is only one therapeutic targeting NRF2 for clinical use, dimethyl fumarate, used for the treatment of multiple sclerosis. The discovery of new therapies is confounded by the fact that NRF2 levels vary significantly depending on physiological and pathological context. Thus, properly timed and targeted manipulation of the NRF2 pathway is critical in creating effective therapeutic regimens. In this review, we summarize the regulation and downstream targets of NRF2. Furthermore, we discuss the role of NRF2 in cancer, neurodegeneration, and diabetes as well as cardiovascular, kidney, and liver disease, with a special emphasis on NRF2-based therapeutics, including those that have made it into clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.